MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain Treatment

MIRA Pharmaceuticals announced the acceptance of a second manuscript detailing Ketamir-2's efficacy in treating neuropathic pain. Published in Frontiers in Pharmacology, the study shows Ketamir-2's superior performance over ketamine, pregabalin, and gabapentin in rodent models. This supports MIRA's plans to advance to Phase 2a clinical trials by the end of 2025.

Neuropathic pain remains a significant issue in North America, affecting 36-51 million people. The market is valued at $7.97 billion in 2024, projected to grow at a CAGR of 7.73% to $16.79 billion by 2034. Ketamir-2, with its unique mechanism and oral bioavailability, positions itself as a potential non-opioid treatment in this expanding market.

Ketamir-2's selectivity for the NMDA receptor and minimal interaction with other receptors highlight its therapeutic promise. MIRA's CEO, Erez Aminov, expressed confidence in Ketamir-2's advancement toward Phase 2a trials, highlighting its efficacy in preclinical models.